Purvalanol B

CHF 60.00
In stock
SYN-1070-M0011 mgCHF 60.00
SYN-1070-M0055 mgCHF 90.00
SYN-1070-M01010 mgCHF 120.00
SYN-1070-M05050 mgCHF 461.00
SYN-1070-M100100 mgCHF 790.00
 
More Information
Product Details
Synonyms NG95
Product Type Chemical
Properties
Formula C20H25ClN6O3
MW 432.9
CAS 212844-54-7
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: CDK2 - CDK7 - CDK5 - CDK4 | Kinase Group: CMGC | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key ZKDXRFMOHZVXSG-HNNXBMFYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Purvalanol B is a cyclin-dependent kinase inhibitor with IC(50) values of 6, 6, 9, > 10,000, and 6nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35, respectively. Purvalanol B has also been shown to have anti-proliferative properties, mediated by p42/p44 MAPK.
Product References
  1. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors: N.S. Gray, et al.; Science 281, 533 (1998)
  2. ATP-site directed inhibitors of cyclin-dependent kinases: N. Gray, et al.; Curr. Med. Chem. 6, 859 (1999)
  3. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol: M. Knockaert, et al.; Oncogene 21, 6413 (2002)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.